SI1771468T1 - CELICE, KI CILJAJO NA TUMORJE IN SO VZGOJENE ZA PROIZVODNJO "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND" (TRAIL) - Google Patents

CELICE, KI CILJAJO NA TUMORJE IN SO VZGOJENE ZA PROIZVODNJO "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND" (TRAIL)

Info

Publication number
SI1771468T1
SI1771468T1 SI200530969T SI200530969T SI1771468T1 SI 1771468 T1 SI1771468 T1 SI 1771468T1 SI 200530969 T SI200530969 T SI 200530969T SI 200530969 T SI200530969 T SI 200530969T SI 1771468 T1 SI1771468 T1 SI 1771468T1
Authority
SI
Slovenia
Prior art keywords
tumor
necrosis factor
trail
quot
inducing ligand
Prior art date
Application number
SI200530969T
Other languages
English (en)
Slovenian (sl)
Inventor
Alessandro M Gianni
Carmelo Carlo-Stella
Francesco Colotta
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of SI1771468T1 publication Critical patent/SI1771468T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SI200530969T 2004-07-29 2005-07-21 CELICE, KI CILJAJO NA TUMORJE IN SO VZGOJENE ZA PROIZVODNJO "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND" (TRAIL) SI1771468T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
EP05764208A EP1771468B1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
SI1771468T1 true SI1771468T1 (sl) 2010-07-30

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200530969T SI1771468T1 (sl) 2004-07-29 2005-07-21 CELICE, KI CILJAJO NA TUMORJE IN SO VZGOJENE ZA PROIZVODNJO "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND" (TRAIL)

Country Status (24)

Country Link
US (1) US20070264231A1 (https=)
EP (2) EP1621550A1 (https=)
JP (1) JP5042826B2 (https=)
KR (1) KR20070047757A (https=)
CN (1) CN101076540B (https=)
AT (1) ATE455847T1 (https=)
AU (1) AU2005266543B2 (https=)
BR (1) BRPI0513855A (https=)
CA (1) CA2571426A1 (https=)
DE (1) DE602005019050D1 (https=)
DK (1) DK1771468T3 (https=)
ES (1) ES2340400T3 (https=)
HR (1) HRP20100227T1 (https=)
IL (1) IL180233A (https=)
MX (1) MX2007001152A (https=)
NO (1) NO20070956L (https=)
NZ (1) NZ552223A (https=)
PL (1) PL1771468T3 (https=)
PT (1) PT1771468E (https=)
RS (1) RS51381B (https=)
RU (1) RU2390558C2 (https=)
SI (1) SI1771468T1 (https=)
WO (1) WO2006010558A1 (https=)
ZA (1) ZA200701231B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080199423A1 (en) * 2004-06-18 2008-08-21 Genentech, Inc. Methods of Using Apo2l Receptor Agonists and Ink Cell Activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
EP2163250B1 (en) * 2007-05-18 2013-01-09 National University Corporation Asahikawa Medical University Anticancer therapy by transplanting vascular endothelial progenitor cells
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
AU2015335607B2 (en) 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
JP6974681B2 (ja) * 2015-07-29 2021-12-01 オーエヌケー セラピューティクス リミテッド 細胞傷害性が増加した改変ナチュラルキラー細胞及びナチュラルキラー細胞株
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
US12220465B2 (en) 2018-11-28 2025-02-11 Washington University Compositions and methods for targeted treatment and imaging of cancer or tumors
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US6852703B1 (en) * 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
AU2001290720A1 (en) * 2000-09-11 2002-03-26 Musc Foundation For Research Development Method and composition for treating tumors by selective induction of apoptosis
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
PL1771468T3 (pl) 2010-07-30
HRP20100227T1 (hr) 2010-07-31
CN101076540A (zh) 2007-11-21
MX2007001152A (es) 2007-04-18
RS51381B (sr) 2011-02-28
WO2006010558A8 (en) 2006-08-24
ATE455847T1 (de) 2010-02-15
IL180233A0 (en) 2007-07-04
IL180233A (en) 2010-12-30
NZ552223A (en) 2009-01-31
AU2005266543B2 (en) 2012-02-02
WO2006010558A1 (en) 2006-02-02
EP1771468B1 (en) 2010-01-20
ZA200701231B (en) 2008-08-27
PT1771468E (pt) 2010-04-20
CA2571426A1 (en) 2006-02-02
CN101076540B (zh) 2012-10-24
EP1621550A1 (en) 2006-02-01
NO20070956L (no) 2007-02-20
JP2008507961A (ja) 2008-03-21
DK1771468T3 (da) 2010-05-25
KR20070047757A (ko) 2007-05-07
EP1771468A1 (en) 2007-04-11
DE602005019050D1 (de) 2010-03-11
RU2390558C2 (ru) 2010-05-27
RU2007107369A (ru) 2008-09-10
HK1110874A1 (en) 2008-07-25
US20070264231A1 (en) 2007-11-15
BRPI0513855A (pt) 2008-05-20
JP5042826B2 (ja) 2012-10-03
ES2340400T3 (es) 2010-06-02
AU2005266543A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
SI1771468T1 (sl) CELICE, KI CILJAJO NA TUMORJE IN SO VZGOJENE ZA PROIZVODNJO "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND" (TRAIL)
EP4592314A3 (en) Single-chain and multi-chain chimeric polypeptides and uses thereof
SG170080A1 (en) Human monoclonal antibodies to o8e
MY140829A (en) Chimeric adenoviruses for use in cancer treatment
CY1125027T1 (el) Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
ECSP088299A (es) Modulacion de la expresion del receptor de glucagon
ATE512200T1 (de) Hydrogele mit wasserstoffbrückenbindungen
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
WO2009004484A3 (en) Trim24 (tifla) as p53 modulator and cancer target
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
ATE459653T1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
MX2009012906A (es) Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer.
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
WO2018169901A8 (en) Synthetic promoters
EA201290759A1 (ru) Антитела
WO2009054878A8 (en) Compositions and methods for the treatment of neoplasia
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
WO2018189661A3 (en) Methods and compounds for treating diabetes
WO2010066046A8 (en) Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms
CY1113659T1 (el) Κατασκευασματα που περιεχουν πολλαπλες κασετες εκφρασης για θεραπεια καρκινου